Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma - PubMed (original) (raw)

. 2019 Dec;129(12):2687-2695.

doi: 10.1002/lary.28051. Epub 2019 May 2.

Affiliations

• PMID: 31046139
• DOI: 10.1002/lary.28051

Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma

Tina L Samuels et al. Laryngoscope. 2019 Dec.

Abstract

Objectives/hypothesis: Gastroesophageal reflux disease and associated metaplasia of the esophagus (Barrett's esophagus [BE]) are primary risk factors for esophageal adenocarcinoma (EAC). Widespread use of acid suppression medications has failed to stem the rise of EAC, suggesting that nonacid reflux may underlie its pathophysiology. Pepsin is a tumor promoter in the larynx and has been implicated in esophageal carcinogenesis. Herein, specimens from the esophageal cancer spectrum were tested for pepsin presence. Pepsin-induced carcinogenic changes were assayed in an esophageal cell culture model.

Study design: Laboratory analysis.

Methods: Pepsin was assayed in reflux and cancer free esophagi, BE, EAC, and esophageal cancer lacking association with reflux (squamous cell carcinoma [SCC]). Refluxed or locally synthesized pepsin was assayed by Western blot. Local synthesis of pepsin and proton pumps was assayed via reverse transcription-polymerase chain reaction. The effect of pepsin on BE and EAC markers was investigated via enzyme-linked immunosorbent assay and quantitative polymerase chain reaction in human esophageal epithelial cells treated with pepsin or control diluent.

Results: Pepsinogen and proton pump mRNA were observed in BE (3/5) and EAC (4/4) samples, but not in normal adjacent specimens, SCC (0/2), or reflux and cancer-free esophagi. Chronic pepsin treatment (0.1-1 mg/mL, 4 weeks) of human esophageal cells in vitro induced BE and EAC markers interleukin 8 and KRT8 and depleted normal esophageal marker KRT10 (P < .05) expression.

Conclusions: Local synthesis of pepsin and proton pumps in BE and EAC is not uncommon. Absence of these molecules in normal (noncancer) esophagi, SCC, and in vitro data support a role for pepsin in reflux-attributed carcinogenic changes in the esophagus.

Level of evidence: NA Laryngoscope, 129:2687-2695, 2019.

Keywords: Barrett's esophagus; Pepsin; cytokeratin profile; esophageal adenocarcinoma; gastric proton pump; interleukin 8.

© 2019 The American Laryngological, Rhinological and Otological Society, Inc.

PubMed Disclaimer

Similar articles

• Local Synthesis of Pepsin in Barrett's Esophagus and the Role of Pepsin in Esophageal Adenocarcinoma.
  Samuels T, Hoekzema C, Gould J, Goldblatt M, Frelich M, Bosler M, Lee SH, Johnston N. Samuels T, et al. Ann Otol Rhinol Laryngol. 2015 Nov;124(11):893-902. doi: 10.1177/0003489415590657. Epub 2015 Jun 15. Ann Otol Rhinol Laryngol. 2015. PMID: 26077392 Free PMC article.
• Pepsinogen/Proton Pump Co-Expression in Barrett's Esophageal Cells Induces Cancer-Associated Changes.
  Stabenau KA, Samuels TL, Lam TK, Mathison AJ, Wells C, Altman KW, Battle MA, Johnston N. Stabenau KA, et al. Laryngoscope. 2023 Jan;133(1):59-69. doi: 10.1002/lary.30109. Epub 2022 Mar 22. Laryngoscope. 2023. PMID: 35315085
• Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.
  Kauttu T, Mustonen H, Vainionpää S, Krogerus L, Ilonen I, Räsänen J, Salo J, Puolakkainen P. Kauttu T, et al. Clin Transl Oncol. 2017 Jan;19(1):58-66. doi: 10.1007/s12094-016-1503-3. Epub 2016 Mar 30. Clin Transl Oncol. 2017. PMID: 27026568 Clinical Trial.
• Molecular Evolution of Metaplasia to Adenocarcinoma in the Esophagus.
  Grady WM, Yu M. Grady WM, et al. Dig Dis Sci. 2018 Aug;63(8):2059-2069. doi: 10.1007/s10620-018-5090-8. Dig Dis Sci. 2018. PMID: 29766388 Free PMC article. Review.
• Cellular origins and molecular mechanisms of Barrett's esophagus and esophageal adenocarcinoma.
  Fang Y, Chen X, Bajpai M, Verma A, Das KM, Souza RF, Garman KS, Donohoe CL, O'Farrell NJ, Reynolds JV, Dvorak K. Fang Y, et al. Ann N Y Acad Sci. 2013 Oct;1300:187-199. doi: 10.1111/nyas.12249. Ann N Y Acad Sci. 2013. PMID: 24117642 Review.

Cited by

• The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes.
  Blaine-Sauer S, Samuels TL, Yan K, Johnston N. Blaine-Sauer S, et al. Int J Mol Sci. 2023 Apr 5;24(7):6765. doi: 10.3390/ijms24076765. Int J Mol Sci. 2023. PMID: 37047737 Free PMC article.
• Cancer Risk in Barrett's Esophagus: A Clinical Review.
  Beydoun AS, Stabenau KA, Altman KW, Johnston N. Beydoun AS, et al. Int J Mol Sci. 2023 Mar 23;24(7):6018. doi: 10.3390/ijms24076018. Int J Mol Sci. 2023. PMID: 37046992 Free PMC article. Review.
• Pepsin and Laryngeal and Hypopharyngeal Carcinomas.
  Yin CY, Zhang SS, Zhong JT, Zhou SH. Yin CY, et al. Clin Exp Otorhinolaryngol. 2021 May;14(2):159-168. doi: 10.21053/ceo.2020.00465. Epub 2020 Jul 24. Clin Exp Otorhinolaryngol. 2021. PMID: 32734742 Free PMC article. Review.
• Topical Alginate Protection against Pepsin-Mediated Esophageal Damage: E-Cadherin Proteolysis and Matrix Metalloproteinase Induction.
  Samuels TL, Blaine-Sauer S, Yan K, Plehhova K, Coyle C, Johnston N. Samuels TL, et al. Int J Mol Sci. 2023 Apr 27;24(9):7932. doi: 10.3390/ijms24097932. Int J Mol Sci. 2023. PMID: 37175640 Free PMC article.
• The panoramic picture of pepsinogen gene family with pan-cancer.
  Shen S, Li H, Liu J, Sun L, Yuan Y. Shen S, et al. Cancer Med. 2020 Dec;9(23):9064-9080. doi: 10.1002/cam4.3489. Epub 2020 Oct 17. Cancer Med. 2020. PMID: 33067881 Free PMC article.

References

BIBLIOGRAPHY

1. 1. Noone AM, Howlader N, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2015. Bethesda, MD: National Cancer Institute; 2018.
2. 1. Vaughan TL, Fitzgerald RC. Precision prevention of oesophageal adenocarcinoma. Nat Rev Gastroenterol Hepatol 2015;12:243-248.
3. 1. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-831.
4. 1. Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011;365:1375-1383.
5. 1. Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 2002;122:26-33.

Publication types

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources

• Full Text Sources

  • Wiley

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • GlyGen glycoinformatics resource

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal